MedTrace Logo

Predictive Factors for COVID-19 in Rheumatology

NCT04567576 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2020-09-28

No results posted yet for this study

Summary

We seek to study the behaviour of Coronavirus infection in patients with rheumatological and/or autoimmune comorbidities, understood as a particular pathophysiological universe with its own risks and eventual benefits, until now fully hypothetical to be confirmed by means of real and recent evidence. On March 12, 2020, an initiative called the Global Alliance for COVID-19 in Rheumatology (The COVID-19 Rheumatology Alliance) arises, as a rapid response of international coordination whose ultimate goal is to serve as help or guideline for all those doctors who seek be faced with receiving, evaluating, understanding and caring for a patient with rheumatological and / or autoimmune diseases in relation to the imminent risk of COVID-19.

Conditions

  • Rheumatic Diseases
  • Covid19

Interventions

DRUG

Disease-modifying antirheumatic drugs (DMARDs)

Within a non-experimental setting, the routine disease-modifying antirheumatic drugs (DMARDs) prescription will be evaluated as the "exposure".

Sponsors & Collaborators

  • Fundación Santa Fe de Bogota

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2021-05-31
Completion
2021-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04567576 on ClinicalTrials.gov